CA-C3-AI
16.2.2021 22:29:13 CET | Business Wire | Press release
C3 AI (NYSE:AI), a leading enterprise AI software provider, today announced the release of major enhancements to its enterprise AI application development platform and AI applications designed to further accelerate digital transformation. Over the past decade, C3 AI has invested continuously in the C3 AI® Suite, its open, secure, and multi-cloud enterprise AI platform that leverages a model-driven architecture, enabling end-to-end enterprise AI including data integration, model development, MLOps, application development, and model governance and maintenance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216006166/en/
The latest release – Version 7.17 – provides new capabilities to track and manage full lineage from data sources to application entities. In addition, the latest release includes new composable machine learning (ML) pipelines for data scientists; enhancements to C3 AI CRM, C3 AI Anti-Money Laundering, C3 AI Energy Management, C3 AI Production Schedule Optimization, and C3 AI Reliability applications; and a new enterprise AI application for the oil and gas industry, C3 AI Well Development Optimization.
“Today’s release introduces even more market-leading features for developers, data scientists, and data engineers, while bringing unparalleled speed to the development of enterprise AI applications,” said C3 AI President and Chief Product Officer Houman Behzadi. “We continue to invest significantly in our enterprise AI platform, wide range of developer tools, and configurable enterprise AI applications to enable a richer and more cohesive developer and user experience to accelerate AI adoption.”
The latest platform enhancements and features available with the C3 AI Suite include:
- Comprehensive data, feature, and model lineage: Improvements to enterprise AI application development tools include a new comprehensive data, feature, and model lineage component that enables developers and end users to understand the lineage of their application and AI/ML results.
- Enhanced time series feature generation: The latest release significantly accelerates feature engineering and model development. Enhancements enable faster feature parameterization, more comprehensive statistical transformations, and improved feature selection for use in C3 AI ML Pipelines.
- New composable ML pipelines: Expanding the ever-growing library of C3 AI ML Pipelines, the latest release includes four new pipelines to accelerate model development, including a deep learning pipe for forecasting and a linear quantile regression pipe for probabilistic predictions. C3 AI ML Pipelines also deliver improved model interpretability support with the addition of SHAP (Shapley Additive Explanations) to the available explainability frameworks.
- Multi-cloud Kubernetes service: As part of the ongoing Kubernetes/OpenShift standardization, the latest release supports the Kubernetes service on all clouds.
- New prebuilt data connectors: Performance and scalability improvements to C3 AI’s Virtual Data Lake framework include connectors to Snowflake, Spark/Databricks, S3, Microsoft Power BI, Azure Data Lake, and Microsoft Dynamics 365 – further expanding the library of prebuilt data connectors on the C3 AI Suite. The new connectors help accelerate data integration and allow engineers to create a virtual data image or ingest data directly into the C3 AI Suite.
- Enhancements to enterprise object models: New additions and enhancements to C3 AI’s suite of prebuilt enterprise object models further accelerate development of AI applications. Cross-industry object models provide functional capabilities, including energy management, equipment and process reliability, fraud detection, inventory optimization, and manufacturing yield optimization. In addition, C3 AI also offers industry-specific object models for manufacturing, financial services, oil and gas, utilities, and defense.
C3 AI also continues to invest in its growing portfolio of enterprise AI applications. Notable enhancements include:
- C3 AI CRM delivers a new AI-based precision revenue forecasting and opportunity scoring feature leveraging both data in traditional CRM systems and external feeds (e.g., financial data, news, commodity prices).
- C3 AI Reliability enhancements include a new module – C3 AI Diagram Parsing – to automatically generate digital twins and object models from piping and instrumentation diagrams (P&IDs). C3 AI Diagram Parsing uses machine vision and natural language processing to parse P&IDs to generate machine-readable asset hierarchies and sensor-to-asset mappings.
- C3 AI Inventory Optimization enhancements include what-if scenario modeling capabilities for inventory analysts to account for the ever-changing dynamics of globally distributed supply chains and optimize for the best operating outcomes.
- C3 AI Production Schedule Optimization enhancements include a new user interface, enhancements to the object model, and additional composable ML pipelines. Modifications to the user interface enable end users to more easily generate, review, and act on AI-based demand forecasts and order line recommendations. The newly available demand planning and scheduling data models and ML pipelines help accelerate model development and deployment for data science teams.
- C3 AI Well Development Optimization is a new oil and gas application that optimizes upstream drilling costs and mitigates non-productive time risks such as stuck pipe, lost circulation, and drilling recovery. The application provides the foundational data model for AI-enabled well development applications, as well as for upstream oil and gas operators to plan and execute drilling operations.
For more information about this new release, please contact sales@c3.ai .
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom